Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 12/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | OGA | O60502 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19853187 | 0.84 | LMNA (0.73) | LMNAARNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10236327 | 0.84 | LMNA (0.73) | LMNAARNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18674645 | 0.83 | LMNA (0.71) | LMNAARNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19846720 | 0.83 | LMNA (0.71) | LMNAARNPC1RAB9ASMN1; SMN2 | |
| Tebatizole SCHEMBL2109373 | 0.81 | LMNA (0.69) | LMNANPC1RAB9ASMN1; SMN2OGA | |
| SCHEMBL4463690 | 0.81 | LMNA (0.68) | LMNAARNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3160202 | 0.80 | LMNA (0.67) | LMNAOGA | |
| Tebatizole SCHEMBL11700804 | 0.80 | LMNA (0.67) | LMNANPC1RAB9ASMN1; SMN2OGA | |
| Hydrochloric Acid SCHEMBL17541653 | 0.79 | LMNA (0.65) | LMNAOGAALDH1A1 | |
| SCHEMBL10185759 | 0.78 | LMNA (0.63) | LMNANPC1RAB9ASMN1; SMN2OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3142638-B1 | COMPOSITION FOR DYEING KERATIN FIBRES, COMPRISING AN OXIDATION BASE AND A PARTICULAR HETEROARYL COUPLER | OREAL (FR) | 2020-08-12 | — | — | EP | claimed |
| US-9993409-B2 | Composition for dyeing keratin fibres, comprising an oxidation base and a particular heteroaryl coupler | L'OREAL (FR) | 2018-06-12 | — | — | US | claimed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230064360-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-03-02 | — | — | US | disclosed |
| US-20220220115-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-07-14 | — | — | US | disclosed |
| US-9993409-B2 | Composition for dyeing keratin fibres, comprising an oxidation base and a particular heteroaryl coupler | L'OREAL (FR) | 2018-06-12 | — | — | US | disclosed |
| US-9993409-B2 | Composition for dyeing keratin fibres, comprising an oxidation base and a particular heteroaryl coupler | L'OREAL (FR) | 2018-06-12 | — | — | US | disclosed |
| US-20170087075-A1 | COMPOSITION FOR DYEING KERATIN FIBRES, COMPRISING AN OXIDATION BASE AND A PARTICULAR HETEROARYL COUPLER | L'OREAL (FR) | 2017-03-30 | — | — | US | disclosed |
| US-20170087075-A1 | COMPOSITION FOR DYEING KERATIN FIBRES, COMPRISING AN OXIDATION BASE AND A PARTICULAR HETEROARYL COUPLER | L'OREAL (FR) | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | LMNA 3799/4885AR 3690/4885NPC1 3514/4885 |
| US-20170087075-A1 | COMPOSITION FOR DYEING KERATIN FIBRES, COMPRISING AN OXIDATION BASE AND A PARTICULAR HETEROARYL COUPLER | KRT18, F12, CBR3 | LMNA 618/4885AR 562/4885NPC1 4834/4885 |
| US-20230064360-A1 | HETEROCYCLES AND USES THEREOF | KRAS, HRAS, TP53 | LMNA 3187/4885AR 1144/4885NPC1 2963/4885 |
| US-20220220115-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | LMNA 3549/4885AR 3772/4885NPC1 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.